<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE pdf2xml SYSTEM "pdf2xml.dtd">

<pdf2xml>
<page number="1" position="absolute" top="0" left="0" height="792" width="612">
	<fontspec id="0" size="22" family="Times" color="#000000"/>
	<fontspec id="1" size="8" family="Times" color="#000000"/>
	<fontspec id="2" size="7" family="Times" color="#000000"/>
<text top="26" left="55" width="517" height="27" font="0"><b>ENCODE DCC Antibody Validation Document</b></text>
<text top="77" left="48" width="81" height="12" font="1">Date of Submission</text>
<text top="347" left="39" width="41" height="12" font="1">Antibody </text>
<text top="359" left="39" width="52" height="12" font="1">Description: </text>
<text top="371" left="39" width="2" height="12" font="1"> </text>
<text top="485" left="84" width="61" height="12" font="1">Species Target</text>
<text top="521" left="84" width="90" height="12" font="1">Validation Method #1</text>
<text top="134" left="291" width="25" height="12" font="1">Email:</text>
<text top="134" left="48" width="27" height="12" font="1">Name:</text>
<text top="215" left="48" width="68" height="12" font="1">Antibody Name:</text>
<text top="215" left="300" width="29" height="12" font="1">Target:</text>
<text top="170" left="192" width="15" height="12" font="1">Lab</text>
<text top="249" left="183" width="44" height="12" font="1">Company/</text>
<text top="261" left="183" width="31" height="12" font="1">Source:</text>
<text top="485" left="300" width="53" height="12" font="1">Species Host</text>
<text top="300" left="336" width="50" height="12" font="1">Lot Number</text>
<text top="294" left="39" width="172" height="12" font="1">Catalog Number, database ID, laboratory </text>
<text top="306" left="39" width="2" height="12" font="1"> </text>
<text top="521" left="300" width="90" height="12" font="1">Validation Method #2</text>
<text top="555" left="84" width="50" height="12" font="1">Purification </text>
<text top="567" left="84" width="33" height="12" font="1">Method</text>
<text top="555" left="300" width="48" height="12" font="1">Polyclonal/ </text>
<text top="567" left="300" width="50" height="12" font="1">Monoclonal</text>
<text top="626" left="30" width="58" height="12" font="1">Reference (PI/</text>
<text top="638" left="30" width="49" height="12" font="1">Publication </text>
<text top="650" left="30" width="52" height="12" font="1">Information)</text>
<text top="674" left="28" width="294" height="12" font="1">Please complete the following for antibodies to histone modifications: </text>
<text top="687" left="28" width="205" height="11" font="2">if your specifications are not listed in the drop-down box,  </text>
<text top="697" left="28" width="155" height="11" font="2">please write-in the appropriate information</text>
<text top="728" left="30" width="59" height="12" font="1">Histone Name</text>
<text top="728" left="156" width="52" height="12" font="1">AA modified</text>
<text top="728" left="327" width="48" height="12" font="1">AA Position</text>
<text top="728" left="444" width="53" height="12" font="1">Modification</text>
<text top="419" left="39" width="29" height="12" font="1">Target </text>
<text top="431" left="39" width="52" height="12" font="1">Description: </text>
<text top="443" left="39" width="2" height="12" font="1"> </text>
<text top="599" left="165" width="51" height="12" font="1">Vendor URL:</text>
<text top="601" left="238" width="186" height="12" font="1">http://www.abcam.com/TBLR1-antibody-ChI</text>
<text top="613" left="238" width="94" height="12" font="1">P-Grade-ab24550.html</text>
<text top="77" left="138" width="27" height="12" font="1">2/3/12</text>
<text top="340" left="95" width="174" height="12" font="1">Recombinant full length protein (Human) </text>
<text top="484" left="150" width="31" height="12" font="1">Human</text>
<text top="520" left="178" width="89" height="12" font="2">Immunoprecipitation</text>
<text top="134" left="326" width="92" height="12" font="1">sglandt@stanford.edu</text>
<text top="134" left="83" width="61" height="12" font="1">Stephen Landt</text>
<text top="214" left="121" width="139" height="12" font="1">Anti-TBLR1 antibody - ChIP Grade</text>
<text top="214" left="339" width="124" height="12" font="1">TBL1XR1 EntrezGeneID:79718</text>
<text top="170" left="230" width="29" height="12" font="1">Snyder</text>
<text top="255" left="239" width="29" height="12" font="1">Abcam</text>
<text top="484" left="361" width="27" height="12" font="1">Rabbit</text>
<text top="300" left="395" width="43" height="12" font="1">GR340121</text>
<text top="300" left="215" width="36" height="12" font="1">ab24550</text>
<text top="520" left="395" width="19" height="12" font="2">ChIP</text>
<text top="561" left="141" width="82" height="12" font="2">Crude (not purified)</text>
<text top="561" left="356" width="43" height="12" font="2">Polyclonal</text>
<text top="412" left="95" width="414" height="12" font="1"> F-box-like protein involved in the recruitment of the ubiquitin/19S proteasome complex to nuclear </text>
<text top="424" left="95" width="451" height="12" font="1">receptor-regulated transcription units. Plays an essential role in transcription activation mediated by nuclear </text>
<text top="436" left="95" width="416" height="12" font="1">receptors. Probably acts as integral component of the N-Cor corepressor complex that mediates the </text>
<text top="448" left="95" width="445" height="12" font="1">recruitment of the 19S proteasome complex, leading to the subsequent proteasomal degradation of N-Cor </text>
<text top="460" left="95" width="309" height="12" font="1">complex, thereby allowing cofactor exchange, and transcription activation</text>
</page>
<page number="2" position="absolute" top="0" left="0" height="792" width="612">
<text top="146" left="52" width="57" height="12" font="1">Validation #1 </text>
<text top="158" left="52" width="34" height="12" font="1">Analysis</text>
<text top="661" left="50" width="143" height="12" font="1">Insert Validation Image (click here)</text>
<text top="43" left="125" width="407" height="12" font="1">COMMENT:  Using antibody ab24550 or NB600-270, we observe a single band in Western blots on </text>
<text top="55" left="125" width="424" height="12" font="1">lysates from cell lines K562 and HeLa S3,  that migrates at a position consistent with the predicted size </text>
<text top="67" left="125" width="424" height="12" font="1">(~56kD) of TBLR1  (Panels A,C).  This band is specifically and efficiently immunoprecipitated from K562 </text>
<text top="79" left="125" width="407" height="12" font="1">lysates by each antibody (Panels B,D). Based on this, ab24550 and NB600-270 are validated by this </text>
<text top="91" left="125" width="39" height="12" font="1">criterion. </text>
</page>
<page number="3" position="absolute" top="0" left="0" height="612" width="792">
	<fontspec id="3" size="10" family="Times" color="#000000"/>
	<fontspec id="4" size="10" family="Times" color="#000000"/>
	<fontspec id="5" size="22" family="Times" color="#000000"/>
	<fontspec id="6" size="8" family="Times" color="#000000"/>
	<fontspec id="7" size="14" family="Times" color="#000000"/>
	<fontspec id="8" size="16" family="Times" color="#000000"/>
<text top="337" left="71" width="627" height="13" font="3"><b>A.  </b>Western blot using antibody ab24550 on nuclear lysates from cell lines GM12878 (Lane1), K562 (Lane2), HeLaS3 </text>
<text top="351" left="71" width="592" height="13" font="4">(Lane3), and HepG2 (Lane4).<b>  B.</b> Immunoprecipitation was performed on nuclear lysates from K562 cells using </text>
<text top="365" left="71" width="636" height="13" font="4">antibody ab24550.  Lane1: Nuclear lysate.  Lane 2: Unbound material from immunoprecipitation with ab24550.  Lane 3: </text>
<text top="380" left="71" width="636" height="13" font="4">Bound material from immunoprecipitation with ab24550.  Lane 4:  Bound material from control immunoprecipitation with </text>
<text top="394" left="71" width="628" height="13" font="4">rabbit IgG.  Arrow indicates band of expected size (56kD) that is highly enriched in the specifically immunoprecipitated </text>
<text top="409" left="71" width="592" height="13" font="4">fraction. <b>C.  </b>Western blot using antibody NB600-270 on nuclear lysates from cell lines GM12878 (Lane1), K562 </text>
<text top="423" left="71" width="627" height="13" font="4">(Lane2), HeLaS3 (Lane3), and HepG2 (Lane4).<b>  D.</b> Immunoprecipitation was performed on nuclear lysates from K562 </text>
<text top="437" left="71" width="609" height="13" font="4">cells using antibody NB600-270.  Lane1: Nuclear lysate.  Lane 2: Unbound material from immunoprecipitation with </text>
<text top="452" left="71" width="629" height="13" font="4">NB600-270.  Lane 3: Bound material from immunoprecipitation with NB600-270.  Lane 4:  Bound material from control </text>
<text top="466" left="71" width="594" height="13" font="4">immunoprecipitation with rabbit IgG.  Arrow indicates band of expected size (56kD) that is highly enriched in the </text>
<text top="481" left="71" width="219" height="13" font="4">specifically immunoprecipitated fraction.  </text>
<text top="495" left="71" width="3" height="13" font="4"> </text>
<text top="53" left="60" width="297" height="27" font="5">Antibody ab24550 (TBLR1) </text>
<text top="81" left="140" width="139" height="27" font="5">Immunoblot/ </text>
<text top="110" left="102" width="215" height="27" font="5">immunoprecipitation</text>
<text top="121" left="313" width="3" height="13" font="4"> </text>
<text top="167" left="97" width="42" height="11" font="1">MW (kD) </text>
<text top="197" left="104" width="19" height="11" font="1">100 </text>
<text top="207" left="104" width="14" height="11" font="1">75 </text>
<text top="224" left="104" width="14" height="11" font="1">50 </text>
<text top="238" left="104" width="14" height="11" font="1">38 </text>
<text top="183" left="104" width="19" height="11" font="1">150 </text>
<text top="253" left="104" width="14" height="11" font="1">25 </text>
<text top="262" left="104" width="14" height="11" font="1">20 </text>
<text top="276" left="104" width="14" height="11" font="1">15 </text>
<text top="298" left="92" width="91" height="11" font="6"><b>Lane:    1    2   3   4 </b></text>
<text top="167" left="73" width="20" height="18" font="7">A. </text>
<text top="300" left="260" width="96" height="11" font="6"><b>Lane:     1   2   3     4 </b></text>
<text top="167" left="266" width="42" height="11" font="1">MW (kD) </text>
<text top="197" left="268" width="19" height="11" font="1">100 </text>
<text top="209" left="268" width="14" height="11" font="1">75 </text>
<text top="227" left="268" width="14" height="11" font="1">50 </text>
<text top="242" left="268" width="14" height="11" font="1">38 </text>
<text top="181" left="268" width="19" height="11" font="1">150 </text>
<text top="258" left="268" width="14" height="11" font="1">25 </text>
<text top="277" left="268" width="14" height="11" font="1">15 </text>
<text top="167" left="242" width="22" height="20" font="8">B. </text>
<text top="53" left="404" width="325" height="27" font="5">Antibody NB600-270 (TBLR1) </text>
<text top="81" left="498" width="139" height="27" font="5">Immunoblot/ </text>
<text top="110" left="460" width="215" height="27" font="5">immunoprecipitation</text>
<text top="121" left="671" width="3" height="13" font="4"> </text>
<text top="167" left="442" width="42" height="11" font="1">MW (kD) </text>
<text top="197" left="449" width="19" height="11" font="1">100 </text>
<text top="207" left="449" width="14" height="11" font="1">75 </text>
<text top="224" left="449" width="14" height="11" font="1">50 </text>
<text top="238" left="449" width="14" height="11" font="1">38 </text>
<text top="183" left="449" width="19" height="11" font="1">150 </text>
<text top="253" left="449" width="14" height="11" font="1">25 </text>
<text top="262" left="449" width="14" height="11" font="1">20 </text>
<text top="276" left="449" width="14" height="11" font="1">15 </text>
<text top="298" left="438" width="93" height="11" font="6"><b>Lane:     1    2   3   4 </b></text>
<text top="167" left="419" width="20" height="18" font="7">C. </text>
<text top="308" left="610" width="99" height="11" font="6"><b>Lane:   1   2   3        4 </b></text>
<text top="167" left="615" width="42" height="11" font="1">MW (kD) </text>
<text top="197" left="618" width="19" height="11" font="1">100 </text>
<text top="209" left="618" width="14" height="11" font="1">75 </text>
<text top="227" left="618" width="14" height="11" font="1">50 </text>
<text top="242" left="618" width="14" height="11" font="1">38 </text>
<text top="181" left="618" width="19" height="11" font="1">150 </text>
<text top="258" left="618" width="14" height="11" font="1">25 </text>
<text top="277" left="618" width="14" height="11" font="1">15 </text>
<text top="167" left="591" width="23" height="20" font="8">D. </text>
</page>
<page number="4" position="absolute" top="0" left="0" height="792" width="612">
<text top="159" left="57" width="57" height="12" font="1">Validation #2 </text>
<text top="171" left="57" width="34" height="12" font="1">Analysis</text>
<text top="643" left="54" width="145" height="12" font="1">Insert Validation Image (Click here)</text>
<text top="698" left="268" width="68" height="10" font="1">Submit by Email</text>
<text top="43" left="130" width="393" height="12" font="1">Comment: Because the overlap of the top 40% of peaks from datasets derived from antibodies </text>
<text top="55" left="130" width="381" height="12" font="1">NB600-270 and ab24550 (compared using standard ENCODE scoring methods) exceeds the </text>
<text top="67" left="130" width="345" height="12" font="1">recommended threshold of 80%, both antibodies meet this criterion for validation. </text>
</page>
<page number="5" position="absolute" top="0" left="0" height="612" width="792">
	<fontspec id="9" size="10" family="Times" color="#2d2d2d"/>
	<fontspec id="10" size="10" family="Times" color="#00a8a9"/>
	<fontspec id="11" size="11" family="Times" color="#000000"/>
	<fontspec id="12" size="14" family="Times" color="#e62400"/>
	<fontspec id="13" size="18" family="Times" color="#000000"/>
<text top="306" left="77" width="3" height="13" font="4"> </text>
<text top="320" left="77" width="147" height="13" font="3"><b>Antibodies/Immunogens:</b> </text>
<text top="334" left="77" width="577" height="13" font="3"><b>NB600-270 :</b> Peptide that maps to a region between residues 100 and 150 of human TBL1-related Protein 1 </text>
<text top="349" left="77" width="55" height="13" font="3"><b>ab24550:</b> </text>
<text top="349" left="132" width="165" height="13" font="9">Recombinant full length protein</text>
<text top="349" left="298" width="10" height="13" font="4">.  </text>
<text top="363" left="77" width="3" height="13" font="4"> </text>
<text top="378" left="77" width="650" height="13" font="3"><b>Comparison</b>: K562 cells were used for ChIP-seq with antibody ab24550 or antibody NB600-270.  Peaks were called from </text>
<text top="392" left="91" width="628" height="13" font="4">replicate experiments using PeakSeq with a .01 q-value cut-off.  Comparisons between experiments were made using </text>
<text top="406" left="91" width="423" height="13" font="4">these peaks according to standard ENCODE replicate comparison parameters (</text>
<text top="421" left="91" width="548" height="13" font="10">http://genome.ucsc.edu/ENCODE/protocols/dataStandards/ChIP_DNase_FAIRE_DNAme_v2_2011.pdf</text>
<text top="421" left="640" width="87" height="13" font="4">; reported is the </text>
<text top="435" left="91" width="604" height="13" font="4">fraction of the  top 40% of peaks in one list that are found in the full list of peaks obtained with the other antibody.  </text>
<text top="191" left="379" width="47" height="16" font="11">TBLR1 </text>
<text top="208" left="365" width="70" height="16" font="11">NB600-270</text>
<text top="191" left="457" width="47" height="16" font="11">TBLR1 </text>
<text top="208" left="451" width="54" height="16" font="11">ab24550</text>
<text top="229" left="308" width="35" height="16" font="11">Total </text>
<text top="246" left="304" width="37" height="16" font="11">peaks</text>
<text top="238" left="381" width="39" height="16" font="11">65216</text>
<text top="238" left="459" width="39" height="16" font="11">38496</text>
<text top="264" left="298" width="52" height="16" font="11">% Peak </text>
<text top="281" left="299" width="50" height="16" font="11">overlap </text>
<text top="271" left="385" width="31" height="18" font="12"><b>82.4</b></text>
<text top="271" left="463" width="31" height="18" font="12"><b>85.8</b></text>
<text top="111" left="88" width="621" height="22" font="13"><b>Validation 2: ChIPseq with alternate antibodies to the same factor</b></text>
<text top="108" left="703" width="7" height="27" font="5"> </text>
<text top="136" left="48" width="7" height="27" font="5"> </text>
</page>
</pdf2xml>
